| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/13/2009 | EP2057989A1 Freeze-dried preparation of 1-methylcarbapenem |
| 05/13/2009 | EP2057988A1 Nail patch |
| 05/13/2009 | EP2057987A1 Pharmaceutical composition containing statin-encapsulated nanoparticle |
| 05/13/2009 | EP2057985A1 Coated tablet |
| 05/13/2009 | EP2057984A1 Retard tablets with hydromorphon |
| 05/13/2009 | EP2057983A1 Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations |
| 05/13/2009 | EP2057982A1 Intranasal compositions |
| 05/13/2009 | EP2057905A1 Composition for moderating Triglyceride and Cholesterol Levels |
| 05/13/2009 | EP2057284A1 Compositions and methods for the modulation of jnk proteins |
| 05/13/2009 | EP2057179A1 Compositions and methods for treating myelosuppression |
| 05/13/2009 | EP2057177A2 Compositions and their uses directed to diacylglycerol acyltransferase 1 |
| 05/13/2009 | EP2057173A1 Amides as sphingomyeline inhibitors |
| 05/13/2009 | EP2057171A1 Selective glycosidase inhibitors and uses thereof |
| 05/13/2009 | EP2057170A2 Polymorphic forms of spirapril hydrochloride |
| 05/13/2009 | EP2057165A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases |
| 05/13/2009 | EP2057164A1 Triazolotriazines as kinase inhibitors |
| 05/13/2009 | EP2057163A1 Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| 05/13/2009 | EP2057162A2 Fused heterocyclic inhibitors of d-amino acid oxidase |
| 05/13/2009 | EP2057161A2 4-oxo-4,5-dihydropyrrolo[1,2-a]quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| 05/13/2009 | EP2057160A1 Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
| 05/13/2009 | EP2057159A1 Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 05/13/2009 | EP2057158A1 Triazole derivatives as kinase inhibitors |
| 05/13/2009 | EP2057157A2 2-amido-4-isoxazolyl thiazole compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 05/13/2009 | EP2057156A1 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| 05/13/2009 | EP2057155A1 1h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitors |
| 05/13/2009 | EP2057153A1 (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl- thiomorpholin-4-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
| 05/13/2009 | EP2057152A1 Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication |
| 05/13/2009 | EP2057149A2 Pseudobase benzo [c]phenanthridines with improved efficacy, stability, and safety |
| 05/13/2009 | EP2057148A1 Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agents |
| 05/13/2009 | EP2057147A1 Pyrimidine derivatives |
| 05/13/2009 | EP2057146A1 Compounds and compositions as protein kinase inhibitors |
| 05/13/2009 | EP2057145A1 Synthesis of (2s,5r)-5-ethynyl-1-{n-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile |
| 05/13/2009 | EP2057144A2 Novel polymorphs of rimonabant |
| 05/13/2009 | EP2057143A2 5-substituted isoindoline compounds |
| 05/13/2009 | EP2057141A1 Pyrimidone compounds as gsk-3 inhibitors |
| 05/13/2009 | EP2057140A1 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| 05/13/2009 | EP2057139A1 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| 05/13/2009 | EP2057138A1 Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same |
| 05/13/2009 | EP2057137A1 R-(-) / s-(+)-7-[3-n-substituted amino-2-hydroxypropoxy]flavones |
| 05/13/2009 | EP2057134A1 Single enantiomer beta agonists method for production and use thereof as a medicament |
| 05/13/2009 | EP2057133A2 Di-amino-substituted heterocyclic compounds and methods of use |
| 05/13/2009 | EP2057131A1 Method of dynamic nuclear polarisation (dnp) and compounds and compositions for use in the method |
| 05/13/2009 | EP2057130A2 Improved method for synthesizing lamotrigine |
| 05/13/2009 | EP2057129A1 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| 05/13/2009 | EP2057128A2 Therapeutic substituted hydantoins and related compounds |
| 05/13/2009 | EP2057127A1 Hydantoin derivatives useful as antibacterial agents |
| 05/13/2009 | EP2057125A1 Non-nucleoside reverse transcriptase inhibitors |
| 05/13/2009 | EP2057124A2 Compounds and compositions as itpkb inhibitors |
| 05/13/2009 | EP2057122A1 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the 2 adrenergic receptor |
| 05/13/2009 | EP2057119A1 3- (ih-indol- 3-ydindan-1-ylamine derivatives for the treatment of depression and anxiety |
| 05/13/2009 | EP2057118A2 Compounds for treatment of proliferative disorders |
| 05/13/2009 | EP2057117A2 Compounds for treating proliferative disorders |
| 05/13/2009 | EP2057116A1 New phenylsulfamoyl benzamide derivatives as bradykinin antagonists |
| 05/13/2009 | EP2057115A1 4-substituted phenoxyphenylacetic acid derivatives |
| 05/13/2009 | EP2057114A1 N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| 05/13/2009 | EP2056883A2 Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| 05/13/2009 | EP2056880A1 Nucleic acid modulation of toll-like receptor-mediated immune stimulation |
| 05/13/2009 | EP2056877A2 Pharmaceutical compositions of benzodiazepines and methods of use thereof |
| 05/13/2009 | EP2056875A1 Novel compositions and methods |
| 05/13/2009 | EP2056871A2 Protein matrix vaccines and methods of making and administering such vaccines |
| 05/13/2009 | EP2056870A2 Trypanosome microsome system and uses thereof |
| 05/13/2009 | EP2056846A2 Salivary substitute |
| 05/13/2009 | EP2056845A2 Structure and use of 5' phosphate oligonucleotides |
| 05/13/2009 | EP2056844A2 Novel macrolides and ketolides having antimicrobial activity |
| 05/13/2009 | EP2056843A2 Use of c7 sugars in prevention and treatment of mycoses |
| 05/13/2009 | EP2056841A1 Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
| 05/13/2009 | EP2056840A2 Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
| 05/13/2009 | EP2056839A1 Combination approaches to cancer treatment |
| 05/13/2009 | EP2056838A2 Combination therapy for treatment of immune disorders |
| 05/13/2009 | EP2056837A1 Aerosol formulation for the inhalation of beta-agonists |
| 05/13/2009 | EP2056836A1 Powder formulations for inhalation containing enantiomerically pure beta-agonists |
| 05/13/2009 | EP2056835A2 Pharmaceutical compositions and uses thereof |
| 05/13/2009 | EP2056834A1 Methods and compositions for increasing patient tolerability during myocardial imaging methods |
| 05/13/2009 | EP2056833A2 Derivatives of uric and thiouric acid for oxidative stress-related diseases |
| 05/13/2009 | EP2056832A1 Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate |
| 05/13/2009 | EP2056831A2 Use of pkc inhibitors in particular indolylmaleimide derivatives in ocular diseases |
| 05/13/2009 | EP2056830A1 Compositions useful especially for treatment or prevention of metabolic syndrome |
| 05/13/2009 | EP2056829A2 Using pi3k and mek modulators in treatments of cancer |
| 05/13/2009 | EP2056828A2 Sulfonylated piperazines as cannabinoid-1 receptor modulators |
| 05/13/2009 | EP2056827A1 Method for inducing tumor apoptosis by increasing nitric oxide levels |
| 05/13/2009 | EP2056826A2 Compositions and methods for increasing blood platelet levels in humans |
| 05/13/2009 | EP2056825A2 Use of opioid formulations in needle-less drug delivery devices |
| 05/13/2009 | EP2056824A2 Topical ceramide compositions and methos of use |
| 05/13/2009 | EP2056823A2 8-hydroxyquinoline compounds and methods thereof |
| 05/13/2009 | EP2056822A1 Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators |
| 05/13/2009 | EP2056821A2 Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders |
| 05/13/2009 | EP2056820A2 A pharmaceutical composition for the treatment of a fungal skin disorder and a method for the preparation thereof |
| 05/13/2009 | EP2056819A2 Cholesterol lowering drug combination |
| 05/13/2009 | EP2056818A2 Compositions and methods for neuroprotection |
| 05/13/2009 | EP2056817A1 Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system |
| 05/13/2009 | EP2056816A2 Lipoxin a4 analogs for the treatment and prevention of intestinal fibrosis |
| 05/13/2009 | EP2056815A1 Use of 2,5-dihydroxybenzene derivatives for treating dermatitis |
| 05/13/2009 | EP2056814A1 2,5-dihydroxybenzene compounds for the treatment of psoriasis |
| 05/13/2009 | EP2056813A1 2,5 dihydroxybenzene compounds for the treatment of rosacea |
| 05/13/2009 | EP2056812A1 Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| 05/13/2009 | EP2056811A2 Modafinil-based treatment for premature ejaculation |
| 05/13/2009 | EP2056810A2 Thiourea compounds |
| 05/13/2009 | EP2056809A1 Ophthalmic percutaneous absorption type preparation |
| 05/13/2009 | EP2056808A2 Small molecule potentiator of hormonal therapy for breast cancer |
| 05/13/2009 | EP2056807A2 Treatment of inflammatory diseases |